ANGPTL4-αvβ3 interaction counteracts hypoxia-induced vascular permeability by modulating Src signalling downstream of vascular endothelial growth factor receptor 2

2016 ◽  
Vol 240 (4) ◽  
pp. 461-471 ◽  
Author(s):  
Elisa Gomez Perdiguero ◽  
Athanasia Liabotis-Fontugne ◽  
Mélanie Durand ◽  
Clément Faye ◽  
Sylvie Ricard-Blum ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Vascular Permeability ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Galectin-1 induces vascular permeability through the neuropilin-1/vascular endothelial growth factor receptor-1 complex

Angiogenesis ◽  
2014 ◽  
Vol 17 (4) ◽  
pp. 839-849 ◽  
Author(s):  
Ming-Heng Wu ◽  
Nien-Wen Ying ◽  
Tse-Ming Hong ◽  
Wei-Fan Chiang ◽  
Yueh-Te Lin ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Vascular Permeability ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Neuropilin 1 ◽  
Endothelial Growth Factor

scholarly journals Neuropilin-1 mediates vascular permeability independently of vascular endothelial growth factor receptor-2 activation

2016 ◽  
Vol 9 (425) ◽  
pp. ra42-ra42 ◽  
Author(s):  
Lise Roth ◽  
Claudia Prahst ◽  
Tina Ruckdeschel ◽  
Soniya Savant ◽  
Simone Weström ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Vascular Permeability ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Neuropilin 1 ◽  
Endothelial Growth Factor

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

2012 ◽  
Vol 03 (02) ◽  
pp. 93-92
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
Vascular Endothelial ◽  
Medulläres Schilddrüsenkarzinom ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Sign in / Sign up

Export Citation Format

Share Document